Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Butantan-DV
- Development stage
- Phase 4
- Lead developer
- Instituto Butantan
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
Butantan-DV is a live-attenuated, tetravalent vaccine developed by Instituto Butantan for the prevention of dengue fever caused by all four serotypes of the dengue virus (DENV-1, DENV-2, DENV-3, and DENV-4). The vaccine is based on technology licensed from the National Institutes of Health (NIH) and utilizes a single-dose administration. It consists of three attenuated strains (DENV-1, DENV-3, and DENV-4) with a specific 30-nucleotide deletion in the 3' untranslated region (Δ30) and a chimeric DENV-2 strain. Phase 3 clinical trial results in Brazil have demonstrated high efficacy, particularly against DENV-1 and DENV-2, and a favorable safety profile across different age groups and regardless of prior dengue exposure.
- Brand names
- Butantan DV
- Other names
- Butantan dengue vaccineTetravalent dengue vaccine TV003
02
Targets
DENV-4 E (Dengue virus serotype 4 envelope protein)DENV-2 E (Dengue virus serotype 2 envelope protein)Dengue virus type 1 envelope glycoprotein EDengue virus type 3 envelope proteinFlavivirus envelope E protein shared epitopes
Beyond the preview
Go deeper on Butantan-DV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Butantan-DV.